J. Swain

NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroend

T. Meyer, J. Cave, Rohini Sharma, 2020, BMJ Open.

Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer

D. Buckley, N. Vasudev, Janet E Brown, 2021, Diagnostics.

NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

J. Cave, Rohini Sharma, A. Lamarca, 2022, Journal of Clinical Oncology.

Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial

Isabelle L Smith, R. Huddart, J. Snowden, 2019, PLoS medicine.

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

J. Cave, Rohini Sharma, D. Cairns, 2023, EClinicalMedicine.

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.

V. Goh, T. Powles, M. Highley, 2023, The Lancet. Oncology.

Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.

C. Ralph, A. Salawu, C. Kelly-Morland, 2024, Health technology assessment.